Is there a real difference between the first onset of efficacy for atypical antipsychotic monotherapies in acute bipolar mania?
Treuer
Tamas
T
Basson
Bruce R
BR
D000208:Acute Disease; D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000068180:Aripiprazole; D001714:Bipolar Disorder / Q000188:drug therapy*; D002986:Clinical Trials as Topic / Q000379:methods; D006801:Humans; D017063:Outcome Assessment, Health Care / Q000706:statistics & numerical data; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data; D015363:Quinolones / Q000494:pharmacology / Q000627:therapeutic use; D012107:Research Design / Q000592:standards; D018967:Risperidone / Q000494:pharmacology / Q000627:therapeutic use; D012680:Sensitivity and Specificity; D013997:Time Factors; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D000068180:Aripiprazole; D018967:Risperidone